Comment From Breakthrough Breast Cancer Suggesting Women Are Missing Out On Aromatase Inhibitors, UK

Main Category: Breast Cancer
Also Included In: Cancer / Oncology
Article Date: 06 Oct 2008 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer, says: "This research shows that the vast majority of breast cancer specialists surveyed were confident that patients in their breast units and who could benefit from Aromatase Inhibitors (AIs) were receiving them in line with NICE guidance. However, it's vital that this is backed up by formal audits to ensure that all patients receive the best treatments for them. "

"For many breast cancer patients, tamoxifen will be the most suitable treatment. However it's important to ensure that patients who may benefit from AIs are identified."

Breakthrough Breast Cancer